Stanford University
Stanford, California, 94304, United States
NCT Number: NCT03919877
With this study the investigators want to understand the physiological differences for people developing pre-diabetes and diabetes. The investigators hypothesize that different individuals go through different paths in the development of the disease. By understanding the personal mechanism for developing disease, the investigators will find a personalized approach to prevent that development. The investigators are also hoping to be able to find a biomarker that will pinpoint to the particular defect and thus, diagnose the problem at an earlier stage and have the information to give personalized diet recommendations to prevent the development of diabetes more effectively.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Stanford, California, 94304, United States
At present, individuals with prediabetes or diabetes are grouped together as a single entity, but almost certainly they represent a mix of different gene-environment interactions that lead to one of four dominant physiologic mechanisms underlying their dysglycemia. 1- liver insulin resistance, 2- muscle insulin resistance, 3- impaired insulin secretion, 4- impaired incretin hormone secretion. Gaps that we are addressing here are extremely important - first, we will define a composite biomarker to identify different subphenotypes of prediabetes based on the four known physiologic mechanisms that contribute differentially in each individual to glucose elevations, which we hypothesize will also be reflected in their "glucotype". Importantly, because both continuous glucose monitor and administration of standardized meal testing and metabolic tests are not practical in the clinic, the development of a composite biomarker comprised of select multi-omics measures and clinical variables will enable clinicians and possibly patients (without clinician) to easily identify the specific diet that will yield optimal health results.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dietary counseling based on results of CGM analyses.
Participants ate a variety of foods, to assess their impact on blood sugars.
Time frame: Assessed at a meal (2 to 6 weeks after baseline), starting just prior eating, for a period of 3 hours
Change in glycemic control measured from baseline through all phases of study, stratified according food type and metabolic sub-type. Glycemic control is derived from continuous glucose monitor (CGM) data and expressed in milligrams/deciliter.
Time frame: Baseline (Day 1)
Classify metabolic subphenotype in individuals without diabetes using a machine learning algorithm applied to the glucose time-series response generated by a 16-point (blood draws) oral glucose tolerance testing (OGTT) done in the clinical research center and at home (using CGM). Participants were categorized as insulin sensitive (IS) if teady state plasma glucose (SSPG) was <120 mg dl-1 and insulin resistant (IR) if their SSPG was ≥120 mg dl-1. For this analysis, disposition index (DI) < 1.58 indicates dysfunctional β-cell function, whereas DI ≥ 1.58 indicates normal β-cell function.
Time frame: Assessed at a meal (2 to 6 weeks after baseline), starting just prior eating, for a period of 3 hours
Measured from baseline through all phases of study, from continuous glucose monitor (CGM) data, and stratified according food type and metabolic sub-type.
Stanford University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06657209
Diabetes, Diabetes Mellitus
Palo Alto, California, United States
View Trial DetailsNCT03558867
Diabetes Mellitus, Diabetes Mellitus, Type 2
Sydney, New South Wales, Australia
View Trial DetailsNCT03292315
Body Weight, Central Nervous System Diseases
West Orange, New Jersey, United States
View Trial DetailsNCT04529473
Glucose Intolerance, Glucose Metabolism Disorders
Chicago, Illinois, United States
View Trial Details